

Obesity Facts

The European Journal of Obesity

Official Organ of

EASO
European Association
for the Study of Obesity



Editorial Representatives


Ellen Blaak, Maastricht
Hermann Toplak, Graz

DAG

Deutsche Adipositas-Gesellschaft

Editorial Representative

Martin Wabitsch, Ulm



Affiliated with

IFSO-EC

International Federation
for the Surgery of Obesity
and Metabolic Disorders –
European Chapter



Editorial Representative

Martin Fried, Prague

Editor-in-Chief

Hans Hauner, München

Assistant Editor

Nora Klötting, Leipzig

Associate Editor

Jennifer Lyn Baker, Frederiksberg

Matthias Blüher, Leipzig

John E. Blundell, Leeds

Ulrich Cuntz, Prien

Carl-Erik Flodmark, Malmö

Martin Fried, Prague

Vojtech Hainer, Prague

Berit L. Heitmann, Copenhagen

Anja Hilbert, Leipzig

Anke Hinney, Essen

Christina Holzapfel, Munich

Jan Kopecký, Prague

John Kral, Brooklyn, NY

Bernhard Ludvik, Vienna

Dragan Micic, Belgrade

Manfred J. Müller, Kiel

Annette Schürmann, Potsdam

Yves Schutz, Lausanne

Pedro Teixeira, Lisbon

Hermann Toplak, Graz

Matthias Tschöp, Neuherberg

Haijun Wang, Beijing

Jane Wardle, London

Kurt Widhalm, Vienna

Tommy Visscher, Zwolle

Editorial Board

Hans-Rudolf Berthoud, Baton Rouge, LA

Ellen Blaak, Maastricht

Karine Clément, Paris

Stefan Engeli, Hannover

I. Sadaf Farooqi, Cambridge

Gema Frühbeck, Pamplona

Susanna Hofmann, Neuherberg

Martin Klingenspor, Freising

Max Lafontan, Toulouse

Julian G. Mercer, Aberdeen

Vidya Mohamed-Ali, London

Dénes Molnár, Pécs

Ruben Nogueiras, Santiago de Compostela

Jean-Michel Oppert, Paris

Andreas F. Pfeiffer, Potsdam

Paul T. Pfluger, Neuherberg

Stephan Rössner, Bromma

Jacob C. Seidell, Amsterdam

Antonio J. Torres, Madrid

Christian Vaisse, San Francisco, CA

Founding Editor

Johannes Hebebrand, Essen

S. Karger GmbH

P.O. Box

D-79095 Freiburg

Editorial Office

Attn. Dr. Sven Riestenpatt

KARGER

Basel · Freiburg · Paris · London · New York · Chennai · New Delhi ·
Bangkok · Beijing · Shanghai · Tokyo · Kuala Lumpur · Singapore · Sydney

T1 – Immunometabolism

T1:PO.046

Acute hyperglycemia increases monocyte and t-lymphocyte content in subcutaneous adipose tissue of healthy obese women

Kračmerová J.^{1,2}, Tencerová M.^{1,2}, Krauzová E.^{1,2}, Mayerová V.^{1,2}, Koc M.^{1,2}, Šiklová M.^{1,2}, Štich V.^{1,2}, Rossmeslová L.^{1,2}

¹Franco-Czech Laboratory for Clinical Research on Obesity, Third Faculty of Medicine, Charles University in Prague, Prague 10, CZ-100 00 Czech Republic, ²Department of Sport Medicine, Third Faculty of Medicine, Charles University in Prague, Prague, CZ-100 00 Czech Republic

Background/Objectives: Hyperglycemia represents one of possible mediators for activation of immune system. It may contribute to worsening of inflammatory state of adipose tissue associated with obesity and thus accelerate the development of metabolic syndrome. The aim of our study was to investigate the effect of a short-term hyperglycemia (HG) on the phenotype and relative content of immune cells in subcutaneous abdominal adipose tissue (SAAT) in obese women without metabolic complications.

Subjects/Methods: Three-hour HG clamp combined with infusion of octreotide (to block insulin secretion) and control investigations with infusion of either octreotide or saline were performed in three groups of obese women (n=10 per group). Before and at the end of the interventions, samples of SAAT were obtained by needle biopsy. The relative content of immune cells in SAAT was determined by flow cytometry. Gene expression analysis of immunity-related markers (chemokines/cytokines, markers of macrophages and lymphocytes, Toll like receptors) in SAAT was performed by quantitative real-time PCR.

Results: In SAAT, HG induced an increase in the content of CD206 negative monocytes/macrophages ($4.9 \pm 0.5\%$ vs. $5.6 \pm 0.5\%$, $p < 0.05$) and T lymphocytes (T helper and T cytotoxic lymphocytes; $3.4 \pm 0.3\%$ vs. $5.6 \pm 0.5\%$ and $1.9 \pm 0.2\%$ vs. $3.1 \pm 0.2\%$ respectively, $p < 0.01$). Further, HG promoted an increase of mRNA levels of immune response markers (CCL2, TLR4, TNF α) and lymphocyte markers (CD3g, CD4, CD8a, TBX21, GATA3, FoxP3) in SAAT ($p < 0.05$). Under both control infusions, none of these changes were observed.

Conclusions: Acute HG increased the content of monocytes and lymphocytes in SAAT of healthy obese women. This result suggests that the short-term HG can modulate an immune status of AT in obese subjects.

Acknowledgement: This work was supported by grant IGA NT 144 86 of Ministry of Health, Collaborative Project ADAPT (www.adapt-eu.net) Contract No. HEALTH-F2-2008-2011 00, UNCE 204015 of Charles University and by grant GAP301/11/0748 of the Grant Agency of the Czech Republic.

T1:PO.047

Role of interleukin 15 in liver fat accumulation in patients with concomitant obesity

Fadijeenko G.D.¹, Babak O.Y.¹, Kolesnikova O.V.¹, Solomentseva T.A.¹, Kurinna O.G.¹, Sytnyk K.O.¹

¹Department of liver and gut diseases, GI

Background: non-alcoholic fatty liver disease (NAFLD) and obesity are associated with low grade inflammation. Experimental data suggest crucial role of interleukin 15 (IL-15) in NAFLD development. Y. Cepero-Donates et al. showed that exceeded secretion of IL-15 promotes fat accumulation in mice. The aim was to investigate IL-15 concentration in patients with NAFLD associated with obesity depending on steatosis degree. The study included 32 patients with NAFLD associated with obesity, 31 normal weight patients with NAFLD and 26 healthy volunteers.

Methods: NAFLD was diagnosed by abdominal ultrasound examination. Steatosis degree was assessed using hepatorenal index (HRI). Obesity was measured using body mass index (BMI) and waist circumference (WC).

Concentration of IL-15 were measured using enzyme-linked immunosorbent assay kit. The results showed that IL-15 concentration was significantly increased in patients with NAFLD comparing to control group. Concentrations of IL-15 observed in NAFLD patients with concomitant obesity were significantly higher than those in NAFLD patients with normal weight ($p < 0,05$). In all NAFLD patients IL-15 correlated with HRI supporting its role in hepatic fat accumulation. Furthermore, in patients with NAFLD there was significant correlations of IL-15 concentration with BMI ($p < 0,05$) and WC ($p < 0,05$).

Conclusions: patients with NAFLD and concomitant obesity might have more significant proinflammatory status that could be caused by adipose tissue dysfunction and abnormal adipocytokines synthesis. Exceeded IL-15 observed in NAFLD patients with obesity supports its role in liver lipid accumulation found in experimental studies. Further investigations are needed to explore correlations of IL-15 with histological findings in NAFLD obese patients.

T1:PO.048

Effect of diet and cd36 deficiency on murine mesenteric lymph nodes

Geys L.¹, Lijnen H.R.¹, Scroyen I.¹

¹Center of Molecular and Vascular Biology, KU Leuven, Leuven, Belgium

Introduction: Mesenteric lymph nodes (MLN) of diet-induced obese mice are smaller than those of lean mice because of atrophy of lymphoid cells. Cluster of differentiation (CD)36 contributes to high fat diet induced obesity (DIO) and is expressed on lymphocytes.

Methods: Five weeks old male wild-type (WT) and CD36 deficient (CD36^{-/-}) mice were kept on standard fat diet (SFD, lean) or on high fat diet (HFD, obese) for 15 weeks. Macrophage content and lymphocyte populations of MLN were analyzed by FACS.

Results: DIO, as compared to SFD feeding, was associated with significantly smaller MLN in WT mice, but not in CD36^{-/-} mice. MLN of obese versus lean mice showed lower prevalence of cytotoxic T cells (TC; CD8⁺), helper T cells (TH; CD4⁺), activated T cells (Tact; CD4⁺CD25⁺) and regulatory T cells (Treg; CD4⁺FoxP3⁺CD25⁺). These differences were not observed between MLN of obese and lean CD36^{-/-} mice. Treg cell content in MLN of WT, but not CD36^{-/-}, mice correlated positively with MLN size. MLN macrophage content was lower for lean than obese WT mice, but was significantly higher for lean as compared to obese CD36^{-/-} mice. Overall, MLN of obese CD36^{-/-} mice contained significantly fewer macrophages as compared to obese WT mice. Analysis of apoptotic markers in MLN revealed lower expression of annexin V and caspase 3 (pro-apoptotic) in MLN of obese CD36^{-/-} versus WT mice, and higher expression of annexin V and FasL for lean CD36^{-/-} versus lean WT mice. Caspase 8, Caspase 9, Bax, AIFm2, Bcl2 and XIAP were not affected by either diet or genotype, thus not supporting differences in apoptosis.

Conclusion: DIO in WT mice, as compared to lean mice, is associated with smaller MLN, lower prevalence of TC, TH, Tact and Treg cells. CD36^{-/-} mice appear to be protected against these changes.

Acknowledgement: Skillful technical assistance by J. Creemer (Clinical Immunology, KU Leuven, Leuven, Belgium) and C. Vranckx is gratefully acknowledged.

T1:PO.049

Nesfatin-1 levels are significantly increased after weight loss induced by bariatric surgery

Krzizek E.C.¹, Brix J.M.², Hoebaus C.¹, Kopp H.P.², Feder A.², Ludvik B.², Scherthaner G.¹, Scherthaner G. H.¹

¹Department of Medicine II, Medical University of Vienna, Vienna, Austria, ²Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria

Background and aims: Nesfatin-1 was recognized as a central novel anorexigenic modulator of food intake and body weight. Thus, nesfatin-1 might be a target to influence hunger and satiety. The peripheral mode

- Silva C., T2:PO.011, T2:PO.012, T8:PO.119
 Silva G., T3:PO.117, T3:PO.127
 Silva L.G., T8:PO.100
 Silva R., T8:PO.011, T8:PO.072
 Silveira L.S., T3:PO.077
 Silventoinen K., T3:OS1.1
 Šimáková M., T2:PO.040
 Simmons C., T4:PO.025
 Simo R., T1:PO.019
 Simo-Servat O., T1:PO.019
 Simoni L., T7:PO.047
 Simonovska V., T7:PO.071
 Sindik J., T3:PO.071
 Sinnakannu J., T1:PO.001
 Sioen I., T2:PO.052
 Sipola-Leppänen M., T5:RS1.4, T4:PO.011
 Siversson C., T8:PO.008
 Siwajek P., T6/T7:OS3.2
 Sjöberg A., T5:OS1.3
 Sjöholm K., T8:OS3.3, T8:PO.014, T8:PO.047, T8:PO.051
 Sjöström D., T8:PO.014
 Sjöström L., T8:OS3.3, T8:PO.014, T8:PO.047, T8:PO.051
 Skelton F., T4:PO.035
 Skjåkødegård H.F., T8:PO.093
 Skjøth T.V., T8:PO.026
 Skoch A., T8:PO.030
 Školníková E., T3:OS3.6
 Škop V., T2:PO.040, T8:PO.030
 Skougaard M., T8:PO.008
 Skrzypulec-Plinta V., T7:PO.079
 Skurk T., T3:OS3.2
 Slack E., T5:PO.003
 Sledzinski M., T1:PO.028
 Sledzinski T., T1:PO.028
 Sliwa A., T1:PO.022
 Smajis S., T8:PO.076
 Smed S., T6:RS1.1
 Smith S., T6/T7:OS3.4, T7:PO.013, T7:PO.014
 Smithson E.F., T3:PO.052
 Šnajder D., T5:PO.016
 Inanc N., T8:PO.013
 Sniehotta F.F., T7:PO.014, T7:PO.019
 So J.Y., T8:PO.097
 Sobleva I.N., T2:PO.069
 Sokejima S., T6:PO.002
 Solanki A., T8:PO.120
 Solmaz A., T8:PO.113
 Solnica B., T1:PO.022, T2:PO.071
 Solomentseva T.A., T1:PO.047
 Soltani H., T5:PO.008
 Somerville R., T4:PO.033
 Sommaruga D., T8:PO.110
 Son B.D., T8:PO.097
 Song J.Y., T3:OS3.3
 Song M., T1:PO.035
 Šonka K., T8:RS2.6
 Soreide H., T8:PO.086
 Sorli J.V., T3:PO.083
 Sousa Novais P.F., T8:PO.060
 Souza A.P., T3:PO.043
 Soylyu M., T3:PO.101, T8:PO.013
 Spahlholz J., T6/T7:OS1.1
 Spahr L., T1:PO.006
 Spalding K.L., T2:RS1.4
 Spanos D., T4:PO.034
 Spasovski M., T7:PO.037, T7:PO.071
 Sperker C., T8:OS1.4, T8:PO.009, T8:PO.027, T8:PO.028
 Spiteri J., T6:PO.018
 Sramkova P., T8:OS1.6, T8:PO.044, T8:PO.048, T8:PO.055
 Střítecká H., T7:PO.081
 St-Pierre D.H., T3:PO.006
 Staels B., T2:PO.018
 Staffler G., T2:PO.009
 Stamenkovic-Pejkovic D.H., T2:PO.045, T8:PO.064
 Stampfer M., T8:OS1.5
 Stancel-Mozwillo J., T1:PO.022
 Standage M., T3:PO.131
 Stankova B., T8:OS1.6, T1:PO.033, T2:PO.036
 Starka L., T2:PO.082
 Stärke F., T7:PO.074
 Stecher L., T5:OS1.4
 Steed L., T7:PO.014
 Steele C., T4:PO.036, T8:PO.127
 Stein G., T2:PO.009
 Steinbring J., T2:PO.006
 Stenblom E.L., T3:PO.011, T3:PO.087
 Stensel D.J., T3:PO.116
 Stepanova N.V., T3:PO.024, T3:PO.040
 Stepien M., T2:PO.042
 Stepnowski P., T1:PO.028
 Stevens L., T8:PO.057
 Štich V., T1:PO.046
 Stillitano I., T5:OS2.4
 Štimac D., T2:PO.016, T8:PO.123
 Stolberg C.R., T3:PO.075
 Stolk R.P., T5:PO.020
 Stolz E., T7:PO.038
 Stotzer U., T2:PO.019
 Stougaard M., T5:PO.021
 Strand B.H., T7:PO.048
 Stratil J., T3:PO.068
 Stratton G., T7:PO.016
 Stritecka H., T3:PO.025, T7:PO.006
 Strnad H., T1:PO.014
 Strømmen M., T4:PO.004
 Stronegger W.J., T7:PO.038
 Struwe C., T3:OS3.3
 Stubbs R.J., T3:OS3.5, T3:PO.094, T4:PO.013, T4:PO.014, T6:PO.011, T7:PO.019
 Stulnig T.M., T2:PO.009
 Stumvoll M., T8:OS1.5, T2:PO.046, T2:PO.070
 Su X., T3:PO.007
 Sudo N., T2:PO.043, T3:PO.095
 Sufi P., T2:PO.077, T8:PO.057
 Suh H., T8:PO.095, T8:PO.096
 SUHRCKE M., T6/T7:OS3.5
 Sui L., T3:PO.134
 Suliburska J., T2:PO.042
 Sumarac-Dumanovic M.S., T2:PO.045, T8:PO.064
 Summerbell C.D., T6/T7:OS3.4, T3:PO.001, T7:PO.013, T7:PO.014, T7:PO.023
 Summerhill K., T3:PO.021
 Sun L., T1:PO.018
 Sun P., T8:PO.063, T8:PO.066
 Sundbom M., T2:PO.028
 Suomalainen A., T1/T2:OS2.2, T2:RS1.3
 Surova M., T1/T2:OS3.1
 Surwillo A., T3:PO.120
 Suslyayeva N.M., T2:PO.069
 Suter M., T8:PL
 Sutherland R., T3:PO.123
 Sutherland W., T4:PO.006
 Svacina S., T8:RS1.3, T3:PO.025
 Svahn B., T2:RS1.4
 Svendsen C.B., T8:OS2.1, T8:PO.022
 Svendsen M., T3:PO.053
 Svensson E., T8:OS3.5
 Svensson P.A., T8:OS3.3, T2:PO.062, T8:PO.047, T8:PO.051
 Svobodova M., T1/T2:OS1.2, T1:RS2.3, T2:PO.030
 Swanenberg I., T3:PO.080
 Syrad H., T3:OS1.2
 Sytnyk K.O., T1:PO.047
 Szökő É., T7:PO.040
 Szulinska M., T2:PO.042
 Tabata A., T3:PO.070
 Tábi T., T7:PO.040
 Tajima K., T6:PO.002
 Tak Y.J., T1:PO.037
 Tanaka K., T7:PO.025
 Tanaka S., T3:PO.091
 Tap J., T2:PO.017
 Tappy L., T2:CS2.4
 Tardelli M., T2:PO.009
 Tase I., T3:PO.103, T3:PO.119
 Taskinen M.R., T8:PO.006
 Taube M., T2:PO.062
 Tavares E., T1:PO.016, T8:PO.106
 Taveira-Gomes A., T6:PO.004
 Taylor B., T5:RS1.3
 Taylor K., T8:OS1.2, T8:PO.109, T8:PO.111, T8:PO.112
 Taylor M., T3:PO.032
 Taylor M.A., T3:PO.136
 Taylor R., T5:RS1.3, T8:PO.002
 Tchernof A., T4:PO.005
 Teixeira P.J., T7:PO.019
 Teixeira D., T6:PO.004
 Tekciec M., T3:PO.109, T7:PO.042
 Temme E.H., T3:RS1.4
 ten Klooster J.P., T1:PO.041
 Tencerova M., T2:PLT1:PO.046
 Teodoru I., T8:PO.001
 Teran-Boaben M., T7:PO.010
 Terraz S., T1:PO.006
 Testa Carvalho L.O., T7:PO.055
 Tetikurt U., T8:PO.113
 Teufel M., T3:PO.049
 Tevfikoglu Alceylan L., T8:PO.029
 Thabuis C., T3:PO.081
 Thalassinou N., T5:PO.026, T7:PO.036
 Theodorakopoulou M., T8:PO.091
 Thiery J., T8:OS1.5
 Thijssen D.H., T8:PO.041
 Thivel D., T3:RS2.2
 Thom G., T8:PO.002
 Thomas E.L., T1:PO.040, T8:PO.049
 Thompson D., T3:PO.074
 Thomsen H.S., T2:PO.022
 Thomsen R.W., T8:OS3.5
 Thorand B., T6/T7:OS2.5, T1:PO.045
 Thorell A., T8:OS2.3, T8:OS3.2